What Does the Evidence Say About Ozempic and Gastroparesis?

Latest update (2026-01)

FDA enforcement record (Ongoing): Presence of Particulate Matter: Hair was found in a prefilled syringe. [source]

From General Health Education to Medication Safety

If you're taking Ozempic and experiencing persistent nausea, vomiting, or abdominal pain, you may be wondering whether the medication could be causing gastroparesis. Building on decades of research into GLP-1 receptor agonists, this page examines what current evidence can and cannot prove about the connection between Ozempic and delayed gastric emptying, and outlines recommended monitoring approaches.

Understanding Ozempic and Its Link to Gastroparesis

Ozempic (semaglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist approved for glycemic control in type 2 diabetes and for weight management. Its pharmacological action includes delayed gastric emptying, which is a known mechanism that can contribute to gastroparesis—a condition characterized by delayed stomach emptying without mechanical obstruction. Clinical presentation of gastroparesis includes nausea, vomiting, early satiety, bloating, and abdominal pain. Diagnosis typically involves gastric emptying scintigraphy or breath tests to confirm delayed emptying. In placebo-controlled trials, gastrointestinal adverse reactions occurred more frequently among patients receiving Ozempic than placebo: placebo 15.3%, Ozempic 0.5 mg 32.7%, and Ozempic 1 mg 36.4% (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). The majority of reports of nausea, vomiting, and/or diarrhea occurred during dose escalation. More patients receiving Ozempic 0.5 mg (3.1%) and Ozempic 1 mg (3.8%) discontinued treatment due to gastrointestinal adverse reactions than patients receiving placebo (0.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). In a trial with Ozempic 1 mg and 2 mg, gastrointestinal adverse reactions occurred more frequently among patients receiving Ozempic 2 mg (34.0%) vs Ozempic 1 mg (30.8%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). These data indicate a dose-dependent increase in gastrointestinal side effects, which may reflect the drug's effect on gastric motility.

Mechanistic Pathways and Clinical Evidence

Mechanistic pathways linking Ozempic to gastroparesis involve GLP-1 receptor activation in the gut, which slows gastric emptying and can lead to symptoms mimicking or exacerbating gastroparesis. Postmarketing reports have noted pulmonary aspiration in patients receiving GLP-1 receptor agonists undergoing elective surgeries or procedures requiring general anesthesia or deep sedation who had residual gastric contents despite reported adherence to preoperative fasting recommendations (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=27f15fac-7d98-4114-a2ec-92494a91da98). This underscores the potential for clinically significant delayed gastric emptying. Available data are insufficient to inform recommendations to mitigate the risk of pulmonary aspiration during general anesthesia or deep sedation in patients taking Rybelsus or Ozempic tablets, including whether modifying preoperative fasting recommendations or temporarily discontinuing these drugs could reduce the incidence of retained gastric contents (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=27f15fac-7d98-4114-a2ec-92494a91da98). Patients are instructed to inform healthcare providers prior to any planned surgeries or procedures if they are taking Rybelsus or Ozempic tablets (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=27f15fac-7d98-4114-a2ec-92494a91da98). Risk anchors for affected patients include the adequacy of warnings regarding Ozempic and gastroparesis. The prescribing information for Ozempic includes warnings about gastrointestinal adverse reactions and hypersensitivity reactions, such as anaphylaxis and angioedema (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). However, the label does not explicitly list gastroparesis as a separate warning, though the delayed gastric emptying effect is recognized. This gap may be relevant for patients who develop severe or persistent symptoms that meet diagnostic criteria for gastroparesis.

Statute of Limitations for Ozempic Claims in Pennsylvania

Settlement-related considerations for patients in Pennsylvania hinge on the statute of limitations for product liability claims. In Pennsylvania, the statute of limitations for personal injury claims is generally two years from the date of injury or from when the injury was discovered or should have been discovered with reasonable diligence. For Ozempic-related gastroparesis, the timeline between exposure and documented harm is critical. Symptoms often emerge during dose escalation or after prolonged use, as seen in clinical trials where gastrointestinal adverse reactions occurred more frequently during dose escalation (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). Patients who develop gastroparesis may need to establish when they first experienced symptoms and when a formal diagnosis was made to determine the start of the limitations period. Settlement-related considerations also involve the strength of evidence linking Ozempic to gastroparesis. The mechanistic plausibility, combined with clinical trial data showing increased gastrointestinal adverse reactions and postmarketing reports of retained gastric contents, supports a causal association. However, individual cases may vary based on pre-existing conditions, concurrent medications, and duration of use. Patients considering legal action should consult with an attorney experienced in pharmaceutical litigation to evaluate their specific circumstances, including the adequacy of warnings and the timing of their injury. In summary, Ozempic use is associated with gastrointestinal adverse reactions that can include symptoms consistent with gastroparesis. The drug's mechanism of delayed gastric emptying, supported by clinical trial data and postmarketing reports, provides a plausible link. Patients in Pennsylvania should be aware of the two-year statute of limitations for personal injury claims and the need to document the timeline of exposure and harm. Legal consultation is recommended to assess individual claims.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the statute of limitations for Ozempic gastroparesis claims in Pennsylvania?

In Pennsylvania, the statute of limitations for personal injury claims, including product liability cases related to Ozempic and gastroparesis, is generally two years from the date of injury or from when the injury was discovered or should have been discovered with reasonable diligence. It is crucial to document the timeline of Ozempic exposure, symptom onset, and formal diagnosis to determine the start of the limitations period. Consulting with an attorney experienced in pharmaceutical litigation is recommended to evaluate your specific case.

How does Ozempic cause gastroparesis?

Ozempic (semaglutide) is a GLP-1 receptor agonist that slows gastric emptying as part of its mechanism of action. This delayed gastric emptying can lead to symptoms consistent with gastroparesis, such as nausea, vomiting, early satiety, bloating, and abdominal pain. Clinical trials have shown a dose-dependent increase in gastrointestinal adverse reactions, and postmarketing reports have noted retained gastric contents in patients undergoing surgery, indicating clinically significant delayed emptying. The prescribing information does not explicitly list gastroparesis as a separate warning, but the delayed gastric emptying effect is recognized.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Ozempic exposure and a confirmed Gastroparesis diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.

Community Resource & Benefit Desk

Request archival records or inquire about member-exclusive transition and benefit programs.